Ocular Therapeutix (OCUL) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
November 10, 2015 4:17 PM ESTAdvances in Clinical Programs Include NDA Submission for DEXTENZA (sustained release dexamethasone, 0.4mg) for the Treatment of Post-Surgical Ocular Pain
Results Reported for Phase 3 Allergic Conjunctivitis and Phase 2b Glaucoma Programs
Conference Call Today at 5:00 pm Eastern Time
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced... More
